Tech Company Financing Transactions
Immune Pharmaceuticals Funding Round
On 3/31/2005, Immune Pharmaceuticals raised funding from Merlin BioMed Group.
Transaction Overview
Company Name
Announced On
3/31/2005
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
550 Sylvan Ave. 101
Englewood Cliffs, NJ 07632
USA
Englewood Cliffs, NJ 07632
USA
Phone
Website
Email Address
Not Recorded
Overview
Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP; OTCQX: IMNP,) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Elliot Maza
Chief Medical Officer
Tony Fiorino
Browse more venture capital transactions:
Prev: 3/31/2005: NuGEN Technologies venture capital transaction
Next: 3/31/2005: Clearsight Systems venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs